

8th February, 2025

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400051

Dear Sir,

Sub: Submission of Unaudited Financial Results & Limited Review Reports (Standalone & Consolidated) for the quarter ended on 31st December, 2024

We refer to our letter dated 1st February, 2025 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended on 31st December, 2024. These results have been reviewed by the Statutory Auditors of the Company and they have provided their limited review reports dated 8th February, 2025.

We are enclosing herewith copy of the said Unaudited Financial Results and Limited Review Reports.


Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December 2024, please find enclosed the Integrated Filing (Financial) for the quarter ended 31st December 2024.

The Board Meeting commenced at 11:30 a.m. and concluded at 12:15 P.m.

This is as per Regulation – 33 and other applicable provisions of the SEBI (LODR) Regulations, 2015.

Thanking you.

Yours faithfully,
for SAKAR HEALTHCARE LIMITED


SANJAY S. SHAH
MANAGING DIRECTOR
(DIN: 01515296)

Encl: As above.

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 31ST DECEMBER, 2024

(Rs. In lakh)

Particulars	Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2024
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from operations	4341.71	4277.81	3722.55	12734.29	11029.29	15335.17
2 Other income	29.78	37.29	23.09	113.05	240.93	317.71
3 Total Income (1+2)	4371.49	4315.10	3745.63	12847.34	11270.22	15652.88
4 Expenses						
a. Cost of Materials consumed	2492.61	2201.30	2065.73	6943.61	5910.87	8505.42
b. Purchases of stock-in-trade			-	-	-	-
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(229.37)	88.47	6.71	(184.46)	(34.91)	(137.67)
d. Employee benefits expense	492.06	545.52	450.52	1576.03	1458.85	1978.38
e. Finance costs	129.96	164.40	179.22	434.16	551.46	759.05
f. Depreciation & amortisation expense	522.87	511.90	444.47	1540.52	1318.49	1805.05
g. Other expenses	410.57	292.40	298.67	1003.26	954.99	1152.68
Total Expenses	3818.70	3803.99	3445.31	11313.12	10159.75	14062.91
5 Profit before exceptional items and tax (3-4)	552.80	511.11	300.32	1534.22	1110.47	1589.97
6 Exceptional items	5.14		-	5.14	-	
7 Profit before tax (5-6)	547.66	511.11	300.32	1529.08	1110.47	1589.97
8 Tax expense:						
Current tax	91.35	85.18	50.18	255.45	185.64	273.65
Deferred tax	94.40	31.48	92.89	354.99	255.45	422.88
MAT Credit Entitlement	(91.35)	(85.18)	(50.18)	(255.45)	(185.64)	(273.65)
9 Profit for the period from continuing operations (7-8)	453.26	479.63	207.43	1174.09	855.02	1167.09
10 Profit from discontinuing operations before Tax	-	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-	-
12 Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13 Profit for the period (9+12)	453.26	479.63	207.43	1174.09	855.02	1167.09



Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@sakarhealthcare.com **Web:** www.sakarhealthcare.com

Particulars		Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
14	Other Comprehensive Income						
	<i>Items that will not be reclassified subsequently to profit or loss</i>						
	Re-measurement gains/(losses) on defined benefit plans	(7.31)	(10.93)	(7.37)	(21.94)	(22.11)	(14.80)
	Income tax relating to items that will not be reclassified to profit or loss	2.03	3.04	2.05	6.10	6.15	4.11
	<i>Items that will be reclassified subsequently to profit or loss</i>						
	Income tax relating to items that will be reclassified to profit or loss		-	-		-	-
	Other Comprehensive Income, net of tax	(5.28)	(7.89)	(5.32)	(15.84)	(15.96)	(10.69)
15	Total Comprehensive Income for the period (13+14)	447.98	471.74	202.11	1158.25	839.06	1156.41
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	2194.99	2174.99	2174.99	2194.99	2174.99	2174.99
17	Reserves excluding Revaluation Reserves						23578.11
18	Earnings Per Share of Rs. 10/- each (for continuing operations)						
	- Basic	2.08	2.17	0.98	5.32	4.17	5.64
	- Diluted	2.08	2.16	0.98	5.31	4.16	5.63
19	Earnings Per Share of Rs. 10/- each (for discontinued operations)						
	- Basic	-	-	-	-	-	-
	- Diluted	-	-	-	-	-	-
20	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
	- Basic	2.08	2.17	0.98	5.32	4.17	5.64
	- Diluted	2.08	2.16	0.98	5.31	4.16	5.63



Corporate Office: 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007

Phone: 079-26584655 **Fax:** 079-26588054

Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@sakarhealthcare.com **Web:** www.sakarhealthcare.com

Notes:

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
3	The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 8 th February, 2025
7	The Company has allotted 2,00,000 Equity Shares to Promoters on conversion of Convertible Warrants in to Equity on Preferential Basis on 27 th December, 2024

Date: 8th February, 2025
Place: Ahmedabad

for SAKAR HEALTHCARE LIMITED



Sanjay S. Shah
SANJAY S. SHAH
MANAGING DIRECTOR
(DIN : 01515296)



**LIMITED REVIEW REPORT ON THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER
AND NINE MONTHS ENDED DECEMBER 31, 2024**

To
The Board of Directors
M/s. Sakar Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results of Sakar Healthcare Limited for the period quarter ended 31st December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J S Shah & Co
Chartered Accountants
FRN : 132059W .

Jaimin S Shah
Partner

Membership No. : 138488

UDIN : 25138488BMAIXS6752

Place : Ahmedabad

Date : 08.02.2025

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED ON 31ST DECEMBER, 2024

(Rs. In lakh)

Particulars		Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2024
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
(Refer Notes Below)							(Audited)
1	Revenue from operations	4341.71	4277.81	3722.55	12734.29	11029.29	15335.17
2	Other income	29.78	37.29	23.09	113.05	240.93	317.71
3	Total Income (1+2)	4371.49	4315.10	3745.63	12847.34	11270.22	15652.88
4	Expenses						
	h. Cost of Materials consumed	2492.61	2201.30	2065.73	6943.61	5910.87	8505.42
	i. Purchases of stock-in-trade			-	-	-	
	j. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(229.37)	88.47	6.71	(184.46)	(34.91)	(137.67)
	k. Employee benefits expense	492.06	545.52	450.52	1576.03	1458.85	1978.38
	l. Finance costs	129.96	164.40	179.22	434.16	551.46	759.05
	m. Depreciation & amortisation expense	522.87	511.90	444.47	1540.52	1318.49	1805.05
	n. Other expenses	410.57	292.40	298.67	1003.26	954.99	1152.68
	Total Expenses	3818.70	3803.99	3445.31	11313.12	10159.75	14062.91
5	Profit before exceptional items and tax (3-4)	552.80	511.11	300.32	1534.22	1110.47	1589.97
6	Exceptional items	5.14		-	5.14	-	
7	Profit before tax (5-6)	547.66	511.11	300.32	1529.08	1110.47	1589.97
8	Tax expense:						
	Current tax	91.35	85.18	50.18	255.45	185.64	273.65
	Deferred tax	94.40	31.48	92.89	354.99	255.45	422.88
	MAT Credit Entitlement	(91.35)	(85.18)	(50.18)	(255.45)	(185.64)	(273.65)
9	Profit for the period from continuing operations (7-8)	453.26	479.63	207.43	1174.09	855.02	1167.09
10	Profit from discontinuing operations before Tax	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Share of profit of associates and joint ventures accounted for using equity method	-	-	-	-	-	-
14	Profit for the period (9+12+13)	453.26	479.63	207.43	1174.09	855.02	1167.09
	Attributable to owner of parent	453.26	479.63	207.43	1174.09	855.02	1167.09
	Attributable to Non-controlling interests	-	-	-	-	-	-



Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Particulars		Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2024 (Audited)
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
(Refer Notes Below)							
15	Other Comprehensive Income						
	<i>Items that will not be reclassified subsequently to profit or loss</i>						
	Re-measurement gains/(losses) on defined benefit plans	(7.31)	(10.93)	(7.37)	(21.94)	(22.11)	(14.80)
	Income tax relating to items that will not be reclassified to profit or loss	2.03	3.04	2.05	6.10	6.15	4.11
	<i>Items that will be reclassified subsequently to profit or loss</i>						
	Income tax relating to items that will be reclassified to profit or loss		-	-		-	-
	Other Comprehensive Income, net of tax	(5.27)	(7.89)	(5.32)	(15.84)	(15.96)	(10.69)
	Attributable to owner of parent	(5.28)	(7.89)	(5.32)	(15.84)	(15.96)	(10.69)
	Attributable to Non-controlling interests						
16	Total Comprehensive Income for the period (14+15)	447.98	471.74	202.11	1158.25	839.06	1156.41
	Attributable to owner of parent	447.99	471.74	202.11	1158.25	839.06	1156.41
	Attributable to Non-controlling interests			-		-	
17	Paid-up equity shares capital (Face Value per share Rs. 10/-)	2194.99	2174.99	2174.99	2194.99	2174.99	2174.99
18	Reserves excluding Revaluation Reserves			-		-	23578.11
19	Earnings Per Share of Rs. 10/- each (for continuing operations)						
	- Basic	2.08	2.17	0.98	5.32	4.17	5.64
	- Diluted	2.08	2.16	0.98	5.31	4.16	5.63
20	Earnings Per Share of Rs. 10/- each (for discontinued operations)						
	- Basic		-	-		-	-
	- Diluted		-	-		-	-
21	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
	- Basic	2.08	2.17	0.98	5.32	4.17	5.64
	- Diluted	2.08	2.16	0.98	5.31	4.16	5.63



Corporate Office: 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007
Phone: 079-26584655 **Fax:** 079-26588054

Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@sakarhealthcare.com **Web:** www.sakarhealthcare.com

Notes:

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
3	The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 8 th February, 2025
7	The Company has allotted 2,00,000 Equity Shares to Promoters on conversion of Convertible Warrants in to Equity on Preferential Basis on 27 th December, 2024

for SAKAR HEALTHCARE LIMITED

Date: 8th February, 2025

Place: Ahmedabad

 **SANJAY S. SHAH**
MANAGING DIRECTOR
(DIN: 01515296)

Corporate Office: 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007

Phone: 079-26584655 **Fax:** 079-26588054



**LIMITED REVIEW REPORT ON THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER
AND NINE MONTHS ENDED DECEMBER 31, 2024**

To
The Board of Directors
M/s. Sakar Healthcare Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Sakar Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/ (loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter ended 31st December 2024 and for the period from 01.10.2024 to 31.12.2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31.12.2024 and the corresponding period from 01.04.2024 to 31.12.2024, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

1) Sakar Oncology Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J S Shah & Co
Chartered Accountants
FRN : 132059W



Jaimin S Shah
Partner
Membership No. : 138488
UDIN : 25138488BMAXT784I
Place : Ahmedabad
Date : 08.02.2025

**B. STATEMENT OF DEVIATION / VARIATION FOR PROCEEDS OF PREFERENTIAL ISSUE
(CONVERSION OF WARRANTS INTO EQUITY)**
Statement on deviation / variation in utilisation of funds raised

Name of listed entity	Sakar Healthcare Limited
Mode of Fund Raising	Preferential Issue (Conversion of Warrants into Equity Shares)
Date of Raising Funds	27-12-2024
Amount Raised	Rs. 5,76,00,000/-
Report filed for Quarter ended	31-12-2024
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	Not applicable
Comments of the auditors, if any	Not applicable

Objects for which funds have been raised and where there has been a deviation, in the following table:

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised till 31-12-2024	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Repayment/ prepayment of all or a portion of certain borrowings from State Bank of India availed by our Company	N.A.	1,45,35,000	N.A.	1,45,35,000	Nil	The funds have been Utilized in total
Capital expenditure for Procurement of Lipid Complex Injections Machinery and Equipments/Utilities with electrification for Oncology unit	N.A.	3,90,65,000	N.A.	NIL	3,90,65,000	Unutilized amount will be utilized within 6 months from receipt of fund
General corporate purposes	N.A.	40,00,000	N.A.	40,00,000	Nil	The funds have been Utilized in total

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

for **SAKAR HEALTHCARE LIMITED**



SANJAY S. SHAI
MANAGING DIRECTOR
(DIN : 01515296)

Date: 8th February, 2025
Place: Ahmedabad

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:

Not Applicable

Sr. No.	Particulars	in INR crore
1.	Loans / revolving facilities like cash credit from banks / financial institutions	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
2.	Unlisted debt securities i.e. NCDs and NCRPS	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	0

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

:Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)

:Not Applicable

